TrkB dimerization during development of the prefrontal cortex of the macaque.
To date, two subtypes of TrkB, a BDNF receptor, have been described. One is full-length TrkB (TK+), which has a tyrosine kinase-containing intracellular domain. The other is truncated TrkB (TK-), which has a short intracellular domain lacking the tyrosine kinase. In this study, we investigated the dimerization of TrkB subtypes in the developing monkey prefrontal cortex by means of cross-linking. At embryonic day 120, the TK+/TK+ and the 100 kDa/100 kDa homodimers were observed with BDNF stimulation. At the newborn stage, the TK+/TK+ and the TK-/TK- homodimers were observed with BDNF stimulation. At the adult stage, the TK-/TK- homodimer and the TK+/TK- heterodimer were formed by BDNF stimulation. The levels of all dimers increased in proportion to the concentration of BDNF. Moreover, the dimers were clearly formed within 5 min of treatment with BDNF. BDNF and NT-4/5 induced the dimers, whereas NT-3 formed slight dimers but NGF did not. Furthermore, anti-BDNF antibody inhibited the TrkB dimerization. Moreover, the intercellular binding proteins of TrkB were not cross-linked by BS3. Therefore, these results suggest that the change in dimerization among TrkB subtypes occurs during development of the monkey prefrontal cortex.
Ohira
K
K
Department of Cellular and Molecular Biology, Primate Research Institute, Kyoto University, Kanrin, Inuyama, Aichi, Japan.
Shimizu
K
K
Hayashi
M
M
D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D019208:Brain-Derived Neurotrophic Factor / Q000276:immunology / Q000378:metabolism* / Q000494:pharmacology; D002454:Cell Differentiation / Q000502:physiology*; D003432:Cross-Linking Reagents / Q000494:pharmacology; D019281:Dimerization; D008251:Macaca / Q000033:anatomy & histology / Q000196:embryology* / Q000378:metabolism; D008252:Macaca fascicularis; D008253:Macaca mulatta; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D017397:Prefrontal Cortex / Q000166:cytology / Q000196:embryology* / Q000378:metabolism; D017434:Protein Structure, Tertiary / Q000187:drug effects / Q000502:physiology; D020813:Receptor, trkB / Q000096:biosynthesis* / Q000187:drug effects / Q000276:immunology; D013388:Succinimides / Q000494:pharmacology; D014909:Wheat Germ Agglutinins / Q000493:pharmacokinetics
D000906:Antibodies; D019208:Brain-Derived Neurotrophic Factor; D003432:Cross-Linking Reagents; D013388:Succinimides; D014909:Wheat Germ Agglutinins; C035760:bis(sulfosuccinimidyl)suberate; D020813:Receptor, trkB